CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex

被引:533
作者
Shi, Xuerong
Leng, Lin
Wang, Tian
Wang, Wenkui
Du, Xin
Li, Ji
McDonald, Courtney
Chen, Zun
Murphy, James W.
Lolis, Elias
Noble, Paul
Knudson, Warren
Bucala, Richard
机构
[1] Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA
[3] Shanxi Agr Univ, Taigu, Peoples R China
[4] E Carolina Sch Med, Greenville, NC 27834 USA
关键词
D O I
10.1016/j.immuni.2006.08.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The macrophage migration inhibitory factor (MIF) receptor (CD74) was cloned recently, but the signaling mechanism is not evident. We hypothesized that signaling requires an additional molecule such as CD44, which activates nonreceptor tyrosine kinases. We utilized the CD74- and CD44-deficient CCS-7/M6 cell to create stable transfectants expressing CD74, CD44, and a truncated CD44 lacking its intracytoplasmic signaling domain. CD74 alone mediated MIF binding; however, MIF-induced ERK1 and ERK2 kinase phosphorylation required the coexpression of full-length CD44. MIF binding was associated with the serine phosphorylation of CD74 and CD44. Investigations that used siRNA or kinase inhibitors indicate that MIF-induced ERK1 and ERK2 activation through CD44 required the Src tyrosine kinase. Studies of CD74, CD44, and CD74-CD44 transformants and corresponding mutant cells showed that CD74 and CD44 were necessary for MIF protection from apoptosis. These data establish CD44 as an integral member of the CD74 receptor complex leading to MIF signal transduction.
引用
收藏
页码:595 / 606
页数:12
相关论文
共 65 条
  • [1] Ligation of the CD44 adhesion molecule inhibits drug-induced apoptosis in human myeloid leukemia cells
    Allouche, M
    Charrad, RS
    Bettaieb, A
    Greenland, C
    Grignon, C
    Smadja-Joffe, F
    [J]. BLOOD, 2000, 96 (03) : 1187 - 1190
  • [2] Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFκB
    Amin, MA
    Haas, CS
    Zhu, K
    Mansfield, PJ
    Kim, MJ
    Lackowski, NP
    Koch, AE
    [J]. BLOOD, 2006, 107 (06) : 2252 - 2261
  • [3] Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase
    Amin, MA
    Volpert, OV
    Woods, JM
    Kumar, P
    Harlow, LA
    Koch, AE
    [J]. CIRCULATION RESEARCH, 2003, 93 (04) : 321 - 329
  • [4] Anderson HA, 1999, J IMMUNOL, V163, P5435
  • [5] An essential regulatory role for macrophage migration inhibitory factor in T-cell activation
    Bacher, M
    Metz, CN
    Calandra, T
    Mayer, K
    Chesney, J
    Lohoff, M
    Gemsa, D
    Donnelly, T
    Bucala, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) : 7849 - 7854
  • [6] MIF IS A PITUITARY-DERIVED CYTOKINE THAT POTENTIATES LETHAL ENDOTOXEMIA
    BERNHAGEN, J
    CALANDRA, T
    MITCHELL, RA
    MARTIN, SB
    TRACEY, KJ
    VOELTER, W
    MANOGUE, KR
    CERAMI, A
    BUCALA, R
    [J]. NATURE, 1993, 365 (6448) : 756 - 759
  • [7] PURIFICATION, BIOACTIVITY, AND SECONDARY STRUCTURE-ANALYSIS OF MOUSE AND HUMAN MACROPHAGE-MIGRATION INHIBITORY FACTOR (MIF)
    BERNHAGEN, J
    MITCHELL, RA
    CALANDRA, T
    VOELTER, W
    CERAMI, A
    BUCALA, R
    [J]. BIOCHEMISTRY, 1994, 33 (47) : 14144 - 14155
  • [8] CD44 is not required for poliovirus replication
    Bouchard, MJ
    Racaniello, VR
    [J]. JOURNAL OF VIROLOGY, 1997, 71 (04) : 2793 - 2798
  • [9] CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration
    Bourguignon, LYW
    Zhu, HB
    Shao, LJ
    Chen, YW
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (10) : 7327 - 7336
  • [10] Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis
    Bozza, M
    Satoskar, AR
    Lin, GS
    Lu, B
    Humbles, AA
    Gerard, C
    David, JR
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (02) : 341 - 346